# Claims and Evidence: Challenge

This file contains all **Challenge** claims with their supporting evidence.

---

## C_27: Challenges in microarray meta-analysis include overcoming different study aims, designs, and populations

**Category**: Challenge  
**Source**: Campain2010  
**Context**: Differing platforms and probe mapping make comparisons difficult; laboratory effects like experimental procedures and sample preparation also contribute.

**Primary Quote**:
> "There are a number of issues associated with applying meta-analysis in gene expression studies. These include problems common to traditional meta-analysis such as overcoming different aims, design and populations of interest. There are also concerns specific to gene expression data including challenges with probes and probe sets, differing platforms being compared and laboratory effects."


---


## C_44: The "tail problem" in Gaussian Mixture Modeling (GMM) refers to non-normally distributed tails of outliers in gene expression data

**Category**: Challenge  
**Source**: Liu2022  
**Context**: GMMchi addresses this by iteratively removing data points from the extreme end of the tail while fitting the remaining points with GMM and using Chi-square fitting.

**Primary Quote**:
> "We coined the phrase the 'tail problem' to describe a non-normally distributed tail that is inadequately dealt with by traditional GMM which assumes input data are all expected to be mixtures of normal distributions."

**Supporting Quotes**:
- "To deal with the tail problem we need to distinguish between a good GMM fit of two normal distributions with different variances and a poor over fit due to a mixture of one or two normal distributions with non-normal tail distributions. To make this distinction we add iterative Chi-square fitting to GMM and call this GMMchi."


---


## C_46: Most state-of-the-art domain adaptation methods face challenges when applied to biological datasets

**Category**: Challenge  
**Source**: Orouji2024  
**Context**: Biological datasets are expensive to collect and have complex feature spaces.

**Primary Quote**:
> "However, most state-of-the-art domain adaptation methods were designed for large-scale data such as images, whereas biological datasets are small-scale, heterogeneous, and complex."


---


## C_47: Specific challenges for applying domain adaptation to biological data include poor sample-to-feature ratios and complex feature spaces

**Category**: Challenge  
**Source**: Orouji2024  
**Context**: These factors can substantially hinder data aggregation and model performance.

**Primary Quote**:
> "Poor sample-to-feature ratios: State-of-the-art DA approaches often require tens of thousands (or even millions) of samples to train, but biological datasets have a few dozens or hundreds of samples."


---


## C_57: Microbial cytometry data present different characteristics compared to immunophenotyping data

**Category**: Challenge  
**Source**: Rubbens2021  
**Context**: This necessitates specialized data analysis pipelines like PhenoGMM.

**Primary Quote**:
> "However, microbial cytometry data have a number of different characteristics. This originates from the fact that bacterial cells are typically much smaller in both cell size and volume than eukaryotic cells, which complicates their detection."

**Supporting Quotes**:
- "As the number of bacterial taxa is much larger than the number of differentiating signals, cytometric distributions of these taxa can highly overlap. This is why automated cell population identification algorithms cannot be directly applied for the analysis of bacterial cytometry data. Consequently, data analysis pipelines should be designed to consider these characteristics."


---


## C_90: RMA cannot be used in clinical settings where samples must be processed individually or in small batches

**Category**: Challenge  
**Source**: McCall2010  
**Context**: This is a fundamental limitation of multiarray methods for clinical deployment.

**Primary Quote**:
> "Furthermore, for microarrays to be used in clinical diagnostics, they must provide information based on single array."

**Supporting Quotes**:
- "The dependence on multiple arrays has 2 drawbacks: (1) RMA cannot be used in clinical settings where samples must be processed individually or in small batches and (2) data sets preprocessed separately are not comparable."


---


## C_96: Mass spectrometry-based proteomics data are inherently biased due to sample handling and instrumentation differences

**Category**: Challenge  
**Source**: Valikangas2018  
**Context**: Batch effects in proteomics manifest as systematic shifts in ionization efficiency and instrument sensitivity.

**Primary Quote**:
> "To date, mass spectrometry (MS) data remain inherently biased as a result of reasons ranging from sample handling to differences caused by the instrumentation. Normalization is the process that aims to account for the bias and make samples more comparable."


---


## C_107: Gene expression classifiers must maintain accuracy when applied to samples processed in different hospitals using different equipment

**Category**: Challenge  
**Source**: Buus2021  
**Context**: This portability requirement is fundamental for clinical translation.

**Primary Quote**:
> "A major weakness in many high-throughput genomic studies is the lack of consideration of a clinical environment where one patient at a time must be evaluated."

**Supporting Quotes**:
- "Multi-parameter prognostic signatures are widely used for the prognostication and treatment guidance of ER+/HER2âˆ’ primary breast cancer patients."
- "Multi-parameter gene-expression-based prognostic signatures are often used to estimate the residual risk of recurrence after surgery to guide patient management."


---


